Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-4180
Abstract: Purpose: To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study. Patients and Methods: This phase Ib, dose-finding, and… read more here.
Keywords: vemurafenib cobimetinib; study; melanoma; year ... See more keywords
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
Sign Up to like & getrecommendations! Published in 2021 at "OncoTargets and therapy"
DOI: 10.2147/ott.s325208
Abstract: Background The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to… read more here.
Keywords: treatment; vemurafenib cobimetinib; response; durable response ... See more keywords
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1022496
Abstract: Background Preclinical and translational evidence suggest BRAF/MEK inhibitors modulate the tumor microenvironment (TME), providing rationale for combination with immunotherapy. Methods This investigator-initiated, phase I trial evaluated pembrolizumab, vemurafenib, and cobimetinib in patients with untreated, BRAFV600E/K… read more here.
Keywords: cobimetinib; phase trial; response; pembrolizumab ... See more keywords